A Phase II, Open-Label Study of Bortezomib (Velcade), Cladribine and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Bortezomib (Primary) ; Cladribine (Primary) ; Rituximab (Primary)
- Indications Follicular lymphoma; Lymphoma; Mantle-cell lymphoma
- Focus Therapeutic Use
- 06 Dec 2016 Results (n=24) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 13 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2021 as reported by ClinicalTrials.gov record.
- 04 Dec 2014 Status changed from recruiting to active, no longer recruiting recruiting as reported by ClinicalTrials.gov record.